Loading…
Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.
Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.
Sells through hospital eye departments and pharmacies, where the main drug is a prescription atropine eye drop that children use to slow myopia (short-sightedness). Because treatment is a long course, repeat purchases drive sales. Other ophthalmic generics go through the same channels.
In one line: A small, eye-drops-only Bausch + Lomb.
Moat: narrow (regulatory licence, brand). Early mover and approval lead in prescription low-dose atropine for pediatric myopia control.
Headquarters: Shenyang, China · Employees: 2,396
Size Shenyang Xingqi Pharmaceutical (300573.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.91B, the 1313th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥36.12 on 6 Nov 2026.
Performance Over six months the shares fell 24.6%, against -5.8% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +10.9%); the operating margin is 32.9% (peer median 14.6%).
Valuation It trades at 13.7× forward earnings against a peer median of 23.0× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 33.2 points above its cost of capital (9.4% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.81B | CN¥2.45B | CN¥1.92B | CN¥1.46B | CN¥1.24B |
| Revenue growth | — | +27% | +32% | +18% | — |
| Gross profit | CN¥2.37B | CN¥1.94B | CN¥1.47B | CN¥1.09B | CN¥950M |
| EBITDA | n/a | CN¥920M | CN¥513M | CN¥349M | CN¥304M |
| Net income | CN¥802M | CN¥696M | CN¥338M | CN¥240M | CN¥212M |
| Free cash flow | CN¥614M | CN¥483M | CN¥218M | CN¥55.6M | -CN¥13.0M |
| Capital expenditure | CN¥277M | CN¥271M | CN¥199M | CN¥262M | CN¥299M |
| Total debt | CN¥106M | CN¥101M | CN¥232M | CN¥91.1M | CN¥26.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenyang Xingqi Pharmaceutical 300573.SZ | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% |
| Santen Pharmaceutical 4536.T | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% |
| Alcon ALC.SW | $37.5B | +22% | -1% | 11% | 21.4× | 12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300573.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.3% | +0.6% | 10th highest of 21 |
| 6-month return | -24.6% | -5.8% | 3rd lowest of 21 |
| Distance from 52-week high | -38.9% | -27.2% | 4th lowest of 21 |
| Revenue growth (TTM) | +16.6% | +10.9% | 6th highest of 21 |
| Operating margin | 32.9% | 14.6% | 2nd highest of 21 |
| Forward P/E | 13.7× | 23.0× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 6.0% | 11.5% | 7th least demanding of 17 |
| Growth delivered (Del g) | +29.1% | +7.6% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | -23.1 pp | +2.2 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | +33.2 pp | -0.8 pp | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |